Beschreibung
The hepatitis C virus (HCV), the silent killer, is endemic worldwide. Therefor, finding novel signatures for HCV progression and response to anti-viral therapies is very important in terms of diagnosis and prognosis of the disease. P53 induces the expression of Fas for triggering apoptosis; an important mechanism for limiting viral replication. This study aims at investigating the impact of P53 rs 1042522 and Fas rs 1800682 genetic polymorphisms at 72 Arg/Pro and -670 A/G respectively on HCV susceptibility and treatment response. Quantitation of HCV-RNA by qRT-PCR and histological scores were performed for every patient, as well as genotyping of HCV-RNA, P53 at 72 Arg/Pro, and Fas at -670 A/G polymorphisms were done for all subjects. In addition, hormonal profiling for all patients and controls were investigated and correlated with the genetic signatures, providing a strong multi-signatures for HCV progression and response.
Autorenporträt
Ahmed A. Abd-Rabou, a doctor researcher at Medical Division of National Research Center in Egypt, received his experiences in Biotechnology and Nanomedicine from Pharmaceutical Research Institute (PRI) of Albany College of Pharmacy and Health Sciences (ACPHS) in the USA. Abd-Rabou published over 15 peer-reviewed publications in the same field.
Herstellerkennzeichnung:
OmniScriptum SRL
Str. Armeneasca 28/1, office 1
2012 Chisinau
MD
E-Mail: info@omniscriptum.com
